Haleon posts healthy first quarter update after UK job cuts May 1, 2024 Revenue at Haleon was up in the first quarter despite its announcement yesterday that it would cut over 400 jobs in the UK, as the consumer healthcare firm posted a quarterly update in line with expectations.
Drugmaker Indivior seeks shareholder approval to move primary listing from London to New York April 25, 2024 Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital's beleaguered bourse.
Angle agrees deal with Astrazeneca for tech to kill cancer cells April 24, 2024 This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment.
AIM-listed biotech firms face crunch votes on London Stock Exchange exits April 14, 2024 Redx Pharma and C4X Discovery have scheduled general meetings this week to vote on proposals for delisting from the London Stock Exchange.
Flush FTSE 100 giant Astrazeneca to give more back to shareholders with dividend hike April 11, 2024 AstraZeneca will increase its annual dividend for the year by $0.20 (16p) to $3.10 (£2.47) per share
Spring Budget 2024: £360m research package to boost British manufacturing March 4, 2024 The Spring Budget will include a £360m funding package to boost British manufacturing, research and development, including electric vehicles and pharmaceuticals.
GSK: Cancer claims plague pharma giant as it settles another Zantac case February 29, 2024 GSK has reached another confidential settlement in a Californian lawsuit that had alleged its best-selling indigestion drug, Zantac, was carcinogenic.
Astrazeneca share price rises as Tagrisso drug shows ‘highly impactful’ results in lung cancer trial February 19, 2024 Results from Tagrisso's Phase III trial showed a "statistically significant and highly clinically meaningful improvement" in progression-free survival.
Redx Pharma denies US listing plan following report February 14, 2024 Redx Pharma has denied it is currently in the process of listing in the US following a report in The Times.
GSK receives Fast Track designation for chronic hepatitis B drug in latest boost for pharma giant February 12, 2024 Pharmaceutical giant GSK has received a special recognition from the US Food and Drug Administration (FDA) for its bepirovirsen drug.